Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candin Challenge Validation with Cosentyx
NCT05522517Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of candida albicans antigen (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Presence and Size of Induration at Day 7. Started Aug 2022; status: completed.
02
Drugs
candida albicans antigen
Beyond the preview
Go deeper on NCT05522517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05522517.